Eastgate Biotech Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-09-16: Form 8-K; Period of report 2019-09-04; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2018-06-08: Form 8-K; Period of report 2018-06-01; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
- 2018-05-07: Form 8-K; Period of report 2012-04-20; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
- 2017-05-25: Form 8-K/A; Period of report 2017-05-24; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-09-16 | 8-K | 2019-09-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 4, 2019, the Company announced the appointment of Bill Abajian as Chief Operating Officer. | eastgatebiotech8-k._9.13.19.htm |
| 2018-06-08 | 8-K | 2018-06-01 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On June 1, 2018, the Board of Directors of EastGate Biotech Corp. (the “Company”) dismissed Anton & Chia LLP (“Anton”) as the Company’s independent registered public accounting firm. | eastgatebiotechnewauditor8kj.htm |
| 2018-05-07 | 8-K | 2012-04-20 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 On April 20, 2018, EastGate Biotech Corp. (the “Company”) issued a $450,000 (the “Note”). 3.02 Reference is made to the disclosure set forth under Item 1.01 above, which is incorporated by reference, in its entirety, into this Item 3.02. | eastgatebiotech8kapril202018.htm |
| 2017-05-25 | 8-K/A | 2017-05-24 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 Reference is made to the disclosure set forth under Item 1.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference. | etbi_8ka.htm |
| 2017-05-22 | 8-K | 2017-05-19 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 Reference is made to the disclosure set forth under Item 1.01 of this Current Report on Form 8-K, which disclosure is incorporated herein by reference. | etbi_8k.htm |
| 2017-05-16 | 8-K | 2017-05-12 | 4.01 Changes in Registrant's Certifying Accountant; 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | 4.01 On May 10, 2017, the Board of Directors of EastGate Biotech Corp. (the “Company”) dismissed Sadler, Gibb & Associates, LLC (“Sadler”) as the Company’s independent registered public accounting firm. 4.02 On or about May 3, 2017, the Board of Directors of EastGate Biotech Corp. (the “Company”), upon the recommendation of the Company’s management and after discussions with the Company’s current independent registered public accounting firm, Sadler, Gibb & Associates, LLC (“Sadler”) concluded the quarterly financial statements for the period ended March 31, 2016, June 30, 2016 and September 30, 2016 (collectively, the “Non-Reliance Periods”) as previously issued should no longer be relied upon and will be restated (the “Non-Reliance Determination”). | etbi_8k.htm |
| 2017-05-01 | 8-K | 2017-04-28 | 1.01 Entry into a Material Definitive Agreement; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 1.01 Entry into a Material Definitive Agreement. | etbi_8k.htm |
| 2016-12-19 | 8-K | 2015-12-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 On December 8th 2016, EastGate Biotech Corp. reached an agreement in principle, with Gunpowder Capital Corp. a Canadian public merchant bank, to assist EastGate Biotech with the proposed Canadian stock listing on the Canadian Stock Exchange (“CSE”). | etbi_8k.htm |
| 2015-06-01 | 8-K | 2015-05-29 | 3.02 Unregistered Sales of Equity Securities | 3.02 On May 22, 2015 Eastgate Biotech Corp., a Nevada corporation (the “Company”) issued an aggregate of 62,285,718 shares of its common stock to its officers, directors and employees as payment for accrued and unpaid wages. | esaq8kstockissuances52915.htm |
| 2015-01-21 | 8-K | 2015-01-21 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective January 15, 2015, Mira Hasanagic resigned as the President of Eastgate Biotech Corp. (the “Company”). | esaq8kperriappointment12115v.htm |
| 2014-12-30 | 8-K | 2014-12-22 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 3.02 From December 22, 2014 through December 29, 2014, Eastgate Biotech Corp. (the "Company") consummated an offering (the "Offering") of an aggregate of 8,125,000 units of its securities (the "Units"), with each Unit consisting of one share of common stock, par value $0.00001 per share (the "each, a "Share", and collectively, the "Shares"), and a 5 year warrant (each, a "Warrant" and collectively, the "Warrants") to purchase one share of common stock at an exercise price of $0.04 per share (each, a "Warrant Share", collectively, the "Warrant Shares" and, together with the Units, the Shares and the Warrants, the "Securities"). | etbi-2014dec30_8k.htm |
| 2014-11-26 | 8-K | 2014-11-26 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On November 20, 2014, Eastgate Biotech Corp. (the “Company”) filed a certificate of amendment (the “Amendment”) to its Restated Articles of Incorporation with the Secretary of State of the State of Nevada in order to effectuate (i) a change in its name to “Eastgate Biotech Corp.” from “Eastgate Acquisitions Corporation” (the “Name Change”) and (ii) an increase of its authorized capitalization to 500,000,000 shares, par value $0.00001 per share,consisting of (x) 450,000,000 shares of common stock and (y) 50,000,000 shares of preferred stock from 100,000,000 shares of common stock, par value of $0.00001 per share (the “Authorized Capital Increase”). | esaq8kcertificateofamendment.htm |
| 2014-09-24 | 8-K | 2014-09-24 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | esaq8kpurine92414edgarv1.htm |
| 2014-03-13 | 8-K | 2014-03-12 | 3.02 Unregistered Sales of Equity Securities | 3.02 On March 10, 2014, Eastgate Acquisitions Corporation (“Eastgate” or the ”Company”) announced that it completed a financing of $1.1 million from the sale of 4,450,000 units to selected investors. | form8kfinancingpressreleasem.htm |
| 2013-01-07 | 8-K | 2013-01-07 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | form8kinvestmentagrdec2013.htm |
| 2012-05-29 | 8-K | 2012-05-29 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.06 Change in Shell Company Status | 1.01 Entry into a Material Definitive Agreement. 2.01 On January 15, 2012 Eastgate Acquisitions Corporation (“Eastgate” or the ”Company”) announced that it had entered into a Patent Acquisition Agreement (“Acquisition Agreement”) to acquire certain products, formulas, processes, proprietary technology and/or patents and patent applications related to pharmaceutical, nutraceutical, food supplements and consumer health products (collectively referred to as the “Acquired Products”). 5.01 As a result of the Acquisition Agreement that closed on May 22, 2012, there has been a change in the voting control of our company and in the board of directors by way of appointing three new directors to our board of directors, which were designated by the seller of the products and technology. 5.02 On May 22, 2011 in connection with the closing of the Acquisition Agreement, our board of directors appointed three new directors to the Board, who also became executive officers. 5.06 As explained more fully in Item 2.01 of this Current Report on Form 8-K, the Company was a “shell company” (as such term defined in Rule 12b-2 under the Exchange Act) immediately before the closing of the definitive Acquisition Agreement on May 22, 2012. | form8ksupermay2012final.htm |
| 2012-02-07 | 8-K | 2012-02-06 | 9.01 Financial Statements and Exhibits | 9.01 Financial Statements and Exhibits. | f8keastgate.htm |
| 2010-04-30 | 8-K | 2010-04-22 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) On April 22, 2010, we dismissed the firm of Pritchett, Siler & Hardy, P.C., Certified Public Accountants (“Pritchett, Siler & Hardy”), as our independent certifying accountants pursuant to the unanimous consent of our Board of Directors. | eastgate-8k042810.htm |
| 2009-11-12 | 8-K | 2009-10-14 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 (a) On November 9, 2009, we dismissed the firm of Seale and Beers, CPAs (“Seale and Beers”) as our independent certifying accountants pursuant to the unanimous consent of our Board of Directors. | eastgate-8kauditor.htm |
| 2009-09-03 | 8-K/A | 2009-08-07 | 4.01 Changes in Registrant's Certifying Accountant; 7.01 Regulation FD Disclosure | 4.01 On August 7, 2009 we filed a report on Form 8-K that our Board of Directors dismissed Moore & Associates, Chartered, our independent registered public accounting firm, on that date. | eastgate-8ka090309.htm |
| 2009-08-07 | 8-K | 2009-08-07 | 4.01 Changes in Registrant's Certifying Accountant | eastgateacq8k.txt |